drugset / Trial / NCT00087555

Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

NCT00087555 ↗

Phase 2 Completed 195 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether Xyrem (sodium oxybate) is effective when used alone to treat the pain and sleep disturbances of fibromyalgia.

Timeline

Start
2004-07
Primary completion
2005-04
Completion
2006-01

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs Xyrem (Sodium Oxybate) 4.5g; p = 0.024; Chi-squared NCT00087555 ↗

registry analysis (superiority or other test); Placebo vs Xyrem (Sodium Oxybate) 6.0g; p = 0.035; Chi-squared NCT00087555 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Oxybate Unknown 4.5 g Oral
Subject Sodium Oxybate Unknown 6 g Oral

Indications